Antibody-drug combination outperforms standard treatment of advanced triple-negative breast cancer
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the ...
Jun 2, 2025
0
28









